MMV's key achievements over the last 20 years

1999

Malaria killed over 1 million people, hitting the poorest in sub-Saharan Africa the hardest


Resistance to chloroquine, key medicine used to control malaria, had spread globally and the drug pipeline was virtually empty


MMV launched to develop new antimalarials for vulnerable populations

2000

First industrial and academic organizations become part of the MMV network: GSK, University of Bristol, London School of Hygiene & Tropical Medicine, SmithKline Beecham, University of California, Roche, University of Nebraska and Swiss TPH

2001

MMV announces core management team

2002

Agreement signed with Shin Poong Pharma and WHO-TDR to develop an artemisinin-based combination therapy (ACT) containing pyronaridine and artesunate (Pyramax®)

2003

Agreement signed with Novartis to develop a child-friendly ACT containing artemether and lumefantrine (Coartem® Dispersible)

2004

Agreement signed with Alfasigma S.p.A, Oxford University and Holley Cotec to develop an ACT containing dihydroartemisinin and piperaquine (Eurartesim®)

2005

First patient enrolled in Pyramax® trial at the Hospital for Tropical Diseases at Mahidol University in Bangkok

2006

After a successful stakeholder review of its 6 years, MMV becomes a “3D” organization, adding “delivery” to its “discovery and development” activities

2007

Major phase III studies completed for Eurartesim® and Pyramax® involving more than 6,000 patients


Bill & Melinda Gates Foundation calls for new global commitment to malaria eradication

2008

First medicine: 2 years earlier than promised: Coartem®Dispersible, developed with partner Novartis, registered by SwissMedic, the first child-friendly ACT approved by a stringent regulatory authority

The “Consortium for ACT Private Sector Subsidy” (CAPSS) pilot launched in Uganda to demonstrate impact on access from subsidizing ACT pricing in rural private sector

MMV announces collaboration with GSK for development of tafenoquine for radical cure of P. vivax malaria

2009

MMV, Drugs for Neglected Diseases initiative (DNDi) and Sanofi launch largest post-approval antimalarial safety cohort event monitoring study of artesunate + amodiaquine (ASAQ Winthrop®) involving 15,000+ patients in Côte d’Ivoire

MMV celebrates its 10th anniversary

2010

2011

2012

Fourth medicine: Shin Poong Pharma’s Pyramax® for acute uncomplicated P. falciparum and P. vivax malaria receives a positive scientific opinion from EMA through Article 58

First molecules with potential for chemoprotection (KAF156 with Novartis and DSM265 with NIH and Takeda) enter clinical development

Eurartesim® deployed in Cambodia to help contain ACT drug resistance

Controlled human malaria infection model comes on stream at QIMR Berghofer in Australia to accelerate drug development: allows drug candidates to be tested in healthy individuals infected with malaria in carefully controlled conditions

2013

Over 230 copies of the Malaria Box delivered to research groups globally

MMV now has 50 staff members and a global network of over 375 partners

Global malaria mortality down by 47% from 2000

2014

2015

2016

Agreement signed with S Kant HEALTHCARE Ltd. to develop a second dispersible, taste-masked formulation of SPAQ for SMC


Pyramax® granules added to WHO’s list of prequalified medicines


UN Sustainable Development Goals launched

2017

2018

Tenth medicine: Strides Shasun’s artesunate rectal capsules receive WHO prequalification


Eleventh medicine: Tafenoquine for radical cure of P. vivax malaria is approved by the US FDA and the Australian TGA


Twelfth medicine: Second manufacturer of injectable artesunate secured – Ipca receives WHO prequalification in December for Larinate® 60


319 Pathogen Boxes shipped to scientists around the world free of charge


Fosun Pharma estimates over 120 million vials of Artesun® delivered since 2010


Ten compounds in MMV’s clinical development portfolio, including potential medicines for children, pregnant women and people suffering from drug-resistant malaria


405,000 deaths from malaria, less than half as many as in 1999

2019

MMV launches Pandemic Response Box in partnership with DNDi to accelerate the discovery of new treatments for pandemic diseases


Thirteenth medicine: S Kant HEALTHCARE Ltd., second manufacturer of SPAQ for SMC, receives Global Fund expert review panel positive opinion, allowing for procurement by malaria-endemic countries with donor funds for one year while prequalification is ongoing


390 million treatments of Novartis’ Coartem® Dispersible delivered to over 50 countries since launch


Over 2.2 million lives saved by MMV-supported medicines


Over 100 staff on the MMV team


MMV celebrates its 20th anniversary